Humanigen Inc's ROA from the first quarter of 2023 to the first quarter of 2022 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Humanigen Inc's ROA in the first quarter of 2023?
Humanigen Inc recorded a cumulative net loss of $-54 million during 12 months ending in the first quarter of 2023, resulting in a negative return on assets (ROA) of -233.88%.

However, within the Healthcare sector 1110 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2023 quarter, so far to 5479, from total ROA ranking in the fourth quarter of 2022 at 6203.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2023) I. Quarter	(Dec 31 2022) IV. Quarter	(Sep 30 2022) III. Quarter	(Jun 30 2022) II. Quarter	(Mar 31 2022) I. Quarter
Y / Y Total Assets Change	-92.83 %	-84.25 %	-66.68 %	-59.38 %	-27.84 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-54	-71	-109	-152	-192
Return On Assets (TTM)	-233.88 %	-179.13 %	-199.56 %	-224.94 %	-224.95 %
HGEN's Total Ranking	# 5479	# 6203	# 5498	# 5617	# 5533
Total Assets (TTM) in million	5	11	26	49	71
Seq. Total Assets Change	-54.3 %	-56.89 %	-47.49 %	-30.67 %	0.37 %
Seq. Net Income Change	-	-	-	-	-

HGEN's 5 Years Annual ROA >> Back to HGEN Management Effectiveness >> Compare HGEN ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 544
Sector	# 1111
Overall	# 5361

Return On Assets Statistics
High	Average	Low
-59.49 %	-373.95 %	-1303.57 %
(Dec 31 2013)		(Mar 31 2020)

Financial Statements
Humanigen Inc's Assets	$ 5 million	HGEN's Balance sheet
Humanigen Inc's Income	$ -4 million	Quarterly HGEN's Income Statement
HGEN's Income by Division		See HGEN's Income by Division

Annual Return On Assets	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020	(Dec 31 2019) FY 2019	(Dec 31 2018) FY 2018
Y / Y Total Assets Change	-84.25 %	4.04 %	12959.66 %	-61.82 %	-17.96 %
Total Assets in million	11	71	68	1	1
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-71	-237	-90	-10	-12
Annual Return On Assets	-631.8 %	-333.02 %	-131.09 %	-1968.26 %	-876.2 %

HGEN's 5 Years Annual ROA >> Back to HGEN Management Effectiveness >> Compare HGEN ROA to its Competitors

More Return On Assets Ratios
HGEN's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
HGEN's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for HGEN's Competitors
Subscribers only: Roa for Humanigen Inc's Suppliers
Subscribers only: Return On Assets for HGEN's Customers

You may also want to know
HGEN's Roi	HGEN's Inventory Turnover Ratio	HGEN's Growth Rates	HGEN's Dividend Comparisons
	HGEN's Profitability Ratios	HGEN's Asset Turnover Ratio	HGEN's Dividend Growth
HGEN's Roe	HGEN's Valuation Ratios	HGEN's Financial Strength Ratios	HGEN's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2023, within Healthcare Sector

ROA

Date modified: 2026-09-18T13:11:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.